New long-term follow-up data from phase II clinical trial of Tepezza (teprotumumab-trbw) in thyroid eye disease

Patients from trial were followed for 51 weeks after their last infusion and for 37 who had Week 72 data, there was sustained response up to one year following completion of treatment in terms of improvement in proptosis, diplopia and clinical activity score.

Source:

Biospace Inc.